Shared decision-making for prostate cancer patients

In this interactive patient case video, you’ll meet a 53-year-old man with metastatic castration-resistant prostate cancer (mCRPC) and explore early treatment intensification with a PARPi plus ARPI combination. 

Along the way, you’ll also discover the SHARE Communication Framework – a simple, five-step approach designed to enhance the quality of your patient interactions and support more collaborative, informed treatment decisions. 

Each letter of the SHARE acronym represents a key element of patient communication: 

S – Success criteria and aim of treatment 
H – How the treatments work 
A – Advantages and disadvantages of each treatment option 
R – Risks and effective management of side effects 
E – Expectations for treatment success 

Throughout the video, you will answer questions at key points and engage with clickable resources to deepen your understanding of: 

• Where PARP inhibitors fit into the treatment pathway for patients with mCRPC, and the associated clinical data 
• The advantages and disadvantages of these treatment options to align with the patient’s goals of treatment 
• How to apply the SHARE communication framework during interactions with patients and how to apply the principles routinely 
  
  

Clinical takeaways

• Shared decision-making enhances patient engagement and supports individualised care in mCRPC treatment 
• Certain PARPi and ARPI combination therapies are effective even in molecularly unselected patients 
• Early treatment intensification with a PARPi plus ARPI combination can lead to improved disease control and better quality of life 
• Personal goals and preferences must be considered alongside clinical efficacy and side effects in every treatment decision